Search

Search Constraints

You searched for: Author/Creator Pomerantz, Mark

Search Results

1. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer. Issue 14 (7th June 2018)

3. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Issue 10 (6th May 2021)

5. Clinical predictors of survival in men with castration‐resistant prostate cancer: Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease. Issue 16 (29th May 2013)

6. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

7. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. (27th August 2020)

8. The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer. Issue 13 (1st August 2017)

9. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Issue 3 (27th October 2015)